wag - utm - master medication therapy management network pharmacy community pharmacist guide change

Download WAG - UTM - Master Medication Therapy Management Network Pharmacy Community Pharmacist Guide Change

Post on 12-Mar-2020

0 views

Category:

Documents

0 download

Embed Size (px)

TRANSCRIPT

  • Medication Therapy Management Network Pharmacy Community Pharmacist Guide

    Change History

    Date Version Description

    04/01/2006 1.0 Initial roll-out

    07/01/2006 1.1 Guide layout, addition of billing instructions

    03/09/2007 1.2 Update to billing forms and instructions, addition of Patient Education Handouts

    07/13/2007 1.3 Update to Polypharmacy Patient Counseling and AOT, IMIE, and C&P Recommendation and Talking Points

    06/25/2008 1.4 Update to billing forms and instructions. Addition of Patient Education Handouts and new AOT opportunity categories.

    5/2009 1.5

    Update to TOC. Update to overview and abbreviations pages. Update to AOT, IMIE Recommendation & Talking Points sections. Update to C&P Rationale & Counseling section. Update to POLY Counseling Points. Update to AOT, IMIE, C&P, and POLY Service Bills. Update to patient-education handouts. Update to AOT, IMIE, C&P, and POLY workflow pages. Update to FAQ section. Update to references where applicable.

  • Version 1.5 June 2009

    MedMonitor®XR Network Pharmacy

    Community Pharmacist Guide

    MedMonitorXR Network Pharmacy Community Pharmacist Guide © 2009 Walgreen Co. All rights reserved. The material contained herein is the confidential property of Walgreens. Any use, copying or reproduction of this

    material, without the prior written permission of an officer of Walgreens is prohibited and may lead to civil and criminal prosecution.

  • MedMonitorXR Network Pharmacy Community Pharmacist Guide © 2009 Walgreen Co. All rights reserved.

    i

    Table of Contents

    Introduction—Section A Abbreviations Guide .......................................................................................... A1 MTM Service Overview .................................................................................... A2

    Appropriateness of Therapy (AOT)—Section B AOT Section Overview .................................................................................... B1 AOT Program Summary.................................................................................... B3 AOT Network Community Pharmacy Workflow.............................................. B5 AOT Recommendation and Talking Points • Patients with diabetes not on lipid-lowering therapy .................................. B7 • Patients with diabetes not on an angiotensin converting enzyme inhibitor or an angiotensin receptor blocker ............................................... B9 • Patients taking long-term glucocorticoid therapy

    not on a prophylactic antiresorptive agent................................................... B11 • Inappropriately treated Asthma ................................................................... B14 • Heart failure patients not on an angiotensin converting enzyme inhibitor or an angiotensin receptor blocker................. B20 • Heart failure patients not on appropriate beta-blocker therapy ................... B22 • Patients with atrial fibrillation not on anticoagulant therapy……..……......B23 • Patients post myocardial infarction not on a beta-blocker…………………B27 • Patients post myocardial infarction not on a lipid-lowering agent……............................................................................B28 • Patients with COPD over utilizing bronchodilators......................................B30 • Patients taking a chronic NSAID not on ulcer prophylaxis………………..B32 • Patients over utilizing acute migraine medications not on preventive therapy……………………………………..…………....B34

    AOT Service Bill and Intervention Assessment Feedback Form……...…….....B36

    Inappropriate Medications in the Elderly (IMIE)—Section C IMIE Section Overview..................................................................................... C1 IMIE Program Summary ................................................................................... C3 IMIE Network Community Pharmacy Workflow ............................................ C5 IMIE Recommendation and Talking Points • Barbiturates.................................................................................................. C7 • Chlorpropamide ........................................................................................... C9 • Gastrointestinal antispasmodics .................................................................. C10 • Indomethacin ............................................................................................... C11 • Ketorolac ..................................................................................................... C12 • Long-acting benzodiazepines ..................................................................... C14 • Meperidine................................................................................................... C16 • Meprobamate ............................................................................................... C17 • Methyldopa.................................................................................................. C18 • Muscle relaxants .......................................................................................... C19 • Nifedipine short-acting................................................................................ C21 • Oxybutynin immediate release .................................................................... C22 • Pentazocine.................................................................................................. C24 • Tertiary tricyclic antidepressants ................................................................ C26 • Thioridazine ................................................................................................ C28 • Trimethobenzamide ..................................................................................... C30 • High-dose benzodiazepines………………………………………………...C31 • Zolpidem High-dose………………………………………………………..C32

    IMIE Service Bill and Intervention Assessment Feedback Form...................... C33

  • MedMonitorXR Network Pharmacy Community Pharmacist Guide © 2009 Walgreen Co. All rights reserved.

    ii

    Compliance and Persistency (C&P)—Section D

    C&P Section Overview...................................................................................... D1 C&P Program Summary .................................................................................... D2 C&P Network Community Pharmacy Workflow.............................................. D4 C&P Rationale and Counseling Points • Disease States, Medication Class, and Rationale ........................................ D6 • General Counseling Points .......................................................................... D11 • Specific Disease State/Medication Counseling Points ................................ D13

    C&P Type 1 New to Therapy Point-of-Service Script ...................................... D17 C&P Type 2 Late Refill Telephone Script......................................................... D19 C&P Service Bill and Intervention Assessment Feedback Form ...................... D22

    Polypharmacy—Section E Polypharmacy Section Overview....................................................................... E1 Polypharmacy Program Summary ..................................................................... E3 Polypharmacy Network Community Pharmacy Workflow............................... E5 Polypharmacy Patient Consultation Package • Cover Letter and Instructions ...................................................................... E7 • Service Bill and Consultation Checklist...................................................... E8 • Personal Medication Record (PMR) – Pharmacist Version ........................ E9 • Personal Medication Record (PMR) – Patient Version............................... E10 • Medication Action Plan (MAP)................................................................... E12 • Pharmacist Satisfaction Survey ................................................................... E13

    Polypharmacy Patient Consultation Package: Step-by-Step Instructions for Completing the Forms ....................................... E14 Polypharmacy Consultation Patient Counseling Points • General counseling points ........................................................................... E32

    FAQs and Common Objections—Section F

    FAQs and Common Objections Section Overview ........................................... F1 MTM Community Pharmacist – Frequently Asked Questions (FAQs) ........... F2 MTM Community Pharmacist – Possible Prescriber and Patient Objections ... F6

    Appendix – Section G Appendix Section Overview.............................................................................. G1 MTM Outstanding Opportunities Report ......................................................... G2

    Patient Education Handouts—Section H Patient Education Section Overview ................................................................. H1 Printable Patient Education Handouts • Cholesterol and Heart Disease • Preventing Complications of Diabetes • What You Need to Know About Type 1 Diabetes • What You Need to Know About Type 2 Diabetes • What You Need To Know About Heart Failure